A framework for mutational signature analysis based on DNA shape parameters

Aleksandra Karolak [1,2,†], Jurica Levatić [1], Fran Supek [1,3,*]

[1] Genome Data Science, Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, 08028 Barcelona, Spain.

[2] Department of Population Sciences and Department of Computational and Quantitative Medicine, Division of Mathematical Oncology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.

[3] Catalan Institution for Research and Advanced Studies (ICREA), 08010 Barcelona, Spain.

[†] present address: Division of Quantitative Science, Department of Machine Learning, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

* correspondence to: fran.supek@irbbarcelona.org

Abstract

The mutation risk of a DNA locus depends on its oligonucleotide context. In turn, mutability of oligonucleotides varies across individuals, due to exposure to mutagenic agents or due to variable efficiency and/or accuracy of DNA repair. Such variability is captured by mutational signatures, a mathematical construct obtained by a deconvolution of mutation frequency spectra across individuals. There is a need to enhance methods for inferring mutational signatures to make better use of sparse mutation data (e.g., resulting from exome sequencing of cancers), to facilitate insight into underlying biological mechanisms, and to provide more accurate mutation rate baselines for inferring positive and negative selection. We propose a conceptualization of mutational signatures that represents oligonucleotides *via* descriptors of DNA conformation: base pair, base pair step, and minor groove width parameters. We demonstrate how such DNA structural parameters can accurately predict mutation occurrence due to DNA repair failures or due to exposure to diverse mutagens such as radiation, chemical exposure, and the APOBEC cytosine deaminase enzymes. Furthermore, the mutation frequency of DNA oligomers classed by structural features

can accurately capture systematic variability in mutagenesis of >1,000 tumors originating from diverse human tissues. A nonnegative matrix factorization was applied to mutation spectra stratified by DNA structural features, thereby extracting novel mutational signatures. Moreover, many of the known trinucleotide signatures were associated with an additional spectrum in the DNA structural descriptor space, which may aid interpretation and provide mechanistic insight. Overall, we suggest that the power of DNA sequence motif-based mutational signature analysis can be enhanced by drawing on DNA shape features.

Introduction

Advances in analysis of mutation signatures are transforming genomics of cancer,[1–5] human populations,[6] and model organisms.[7] Tumor evolution is characterized by distinctive somatic mutational processes resulting from mutagen exposures (environmental or endogenous) or defects in DNA repair mechanisms that result in genome instability.[8–10] Identification of these mutational processes can add to our knowledge of DNA damage and repair mechanisms that operate in human cells;[11,12] it can contribute to understanding the etiology of various tumor types, with implications for predicting cancer risk;[13,14] it can improve statistical methodologies for detecting cancer driver genes by refining baseline estimates of mutation rates;[15,16] and finally, it has the potential to identify mutational biomarkers that can aid diagnostics[17,18] and personalized treatment of tumors.[19–21]

The genomic landscapes of individual cancers result from a combination of multiple overlapping mutational processes, making their deconvolution from genomic data a difficult challenge. There are many existing approaches to address this task[22], which apply a factorization technique to a frequency table of occurrences of mutations in various DNA contexts. The resulting mutational signatures can identify known examples of mutagenic mechanisms operative in certain cancer types.[1,2,19] However, many outstanding issues remain with methodologies for extracting mutational signatures. Firstly, many of the signatures were not matched with a mechanism or a clear biological

covariate,[1] which could represent novel biology but can often result from either incompletely/inaccurately resolved mixtures of mutational processes, or sequencing/alignment/mutation calling artefacts. Additionally, the existing mutational signature extractions do not appear very robust: various statistical approaches to infer mutational signatures do not necessarily extract consistent sets of mutational signatures, and moreover even with the same method, minor perturbations to the input data (e.g. same biological process across different tissues) can result in different extracted signatures. One reason for the lack of robustness is that the somatic mutation frequency data tend to be sparse; noise due to low mutation counts can overwhelm biological signal. This is aggravated when changing the tabulation of oligonucleotides from the commonly used trinucleotide (3 nt) DNA sequence representation, to longer, more informative representations – pentanucleotides (5 nt) or heptanucleotides (7 nt) – where the combinatorially increasing number of possible oligonucleotides aggravates sparseness. In addition to these statistical considerations, there are difficulties with interpreting the signatures: DNA sequence is usually not in obvious ways related to the biochemical aspects of the DNA damage and repair processes, and so the sequence-based mutational signatures do not facilitate insight into underlying mechanisms.

To address the challenges above, there may be benefits to enhancing the DNA oligomer representation for mutation signature analysis. Firstly, robustness (towards noise and systematic biases) of the methodologies for signature inference may be improved by reducing data sparseness. Secondly, the ability to interpret the signatures and link them to biological mechanisms may benefit. Thirdly, new representations can help identify additional mutational signatures that are not 'visible' to the standard trinucleotide/pentanucleotide approach. Here, we propose a framework to integrate information about DNA structure[23,24] of the DNA oligomers to predict their mutability and to infer mutation signatures. We were inspired by the known examples of DNA structural features susceptible to certain mutagens, such as DNA hairpin structures vulnerable to the APOBEC3A cytosine deaminase,[25] various other types of DNA repeats with tendency to form non-B-DNA conformations,[26] high curvature of longer DNA segments that associates with mutation rates,[27] or DNA structure changes upon AP-1 transcription

factor binding that sensitizes to UV damage and consequently mutation.[28,29] Our framework generalizes over these examples, employing a diverse set of DNA shape features to describe neighborhoods of mutated loci in human cancer. Our implementation utilizes precalculated base-pair, base-pair step, and minor groove shape parameters of DNA oligomers.[30,31] Such structural parameters are considered to be an accurate description of DNA conformation, summarizing atomic coordinates of nucleotides in a compact representation.[32–34] DNA susceptibility to mutagenic agents or recognition by DNA repair enzymes might be enhanced or disrupted by genetic differences in the regions flanking the mutation site.[35,36] Because DNA predictably acquires a sequence-dependent local conformation, this provides a rationale for implementing sequence-derived DNA shape parameters into a framework to predict and classify mutagenic processes.

Materials and methods

Obtaining somatic mutations from cancer genomic data

We extracted somatic single-nucleotide variants (SNVs; henceforth: mutations) from the whole-genome sequences (WGS) of tumors from 30 cancer types; we did not consider indels or structural variation. The called mutations from cancer WGS were collected from: (i) The Cancer Genome Atlas (TCGA, https://www.cancer.gov/tcga), studies: BLCA, BRCA, CESC, COAD, DLBC, GBM, HNSC, KICH, KIRC, KIRP, LGG, LIHC, LUAD, LUSC, OV, PRAD, READ, SARC, SKCM, STAD, THCA, UCEC; (ii) International Cancer Genome Consortium data portal (ICGC, https://icgc.org), including somatic mutations from studies CLLE-ES, ESAD-UK, LIRI-JP, MALY-DE, MELA-AU, PACA-IT, RECA-EU; and (iii) samples downloaded from the websites of individual WGS study of MDBA.[37] The final list included over 1,600 tumor samples, for which the chromosome number and coordinate of each somatic mutation were extracted using R 3.6.[38] Next, DNA motifs up to +/- three nucleotides flanking each mutation site were retrieved using human GRCh37/hg19 as reference genome. This resulted in tri, penta, and heptanucleotide sequences (“3nt”, “5nt”, “7nt”, respectively) with the mutation placed in

the central position of the oligonucleotide. For the Poisson regression analyses (see below), all three types of DNA sequence motifs were further processed to count their mutation frequency in each tumor sample, and, as a baseline, their overall occurrence in the human genome. For the Principal Component (PC) analysis, each set of mutations (sorted by tri, penta or heptanucleotide) in a given tumor sample was further separated into six mutation outcomes: C>A, C>G, C>T, T>A, T>C and T>G (these are equivalent to, and were considered together with G>T, G>C, G>A, A>T, A>G and A>C, respectively, due to DNA strand symmetry).

DNA representation using structural features

Within pentanucleotide DNA motifs, we extracted various structural parameters thereof. This produced: one minor groove width parameter defined for the central nucleotide (*mgw*0); six base pair (bp) parameters: propeller (*prop*0), opening (*open*0), buckle (*buck*0), stretch (*stre*0), stagger (*stag*0), shear (*shea*0); and additionally six base-pair step parameters, each preceding and following the central nucleotide (thus times two), resulting in total of twelve base-pair step parameters: twist (*tw*-1, *tw*+1), roll (*ro*-1, *ro*+1), tilt (*ti*-1, *ti*+1), slide (*sl*-1, *sl*+1), rise (*ri*-1, *ri*+1), and shift (*sh*-1, *sh*+1).[30] DNA shape parameters extraction was performed using DNAshape R routine,[39,40] which uses the Curves+ algorithm.[41] The total number of parameters increased from nineteen (1+6+12) for the pentanucleotide-based DNA structure representation ("5nt-str") to forty five for the heptanucleotide-based DNA structure representation (3+18+24; "7nt-str"). An illustration of the relationship between nucleotide position and the DNA structural parameters is shown for minor groove width, base-pair parameter propeller, and the base-pair step parameter roll in Figure 1. After extraction of the most informative parameters: minor groove width, propeller, twist, and roll, values of each parameter were normalized to range from 0 to 1, and discretized into three equally distributed bins: high ("H"), medium ("M"), and low ("L"), based on the known, nearly symmetrical distributions of the shape parameters around their equilibrium values.[31]



Figure 1. Mapping of the structural DNA parameters on DNA sequence, where N can be any of the four DNA bases: A (adenine), C (cytosine), G (guanine), or T (thymine). Structural features: minor groove width (mgw), base-pair parameters (bp, shown for propeller), and base-pair step parameters (bp step, shown for roll) and their position within the (A) 5nt-long and (B) 7nt-long DNA motifs.

Modelling mutation counts in oligonucleotides by Poisson regression

The DNA sequence features on the one hand, and DNA shape parameters on the other hand, were applied to the task of predicting the mutation propensity of each oligonucleotide, for six individual hypermutated tumor samples (described below in the Results section), using count modelling and in particular the Poisson regression analysis as implemented in the R environment via the *glm* function.[42] For DNA sequence features, particular each trinucleotide or pentanucleotide was a data point in the regression and was described by the DNA sequence motif features (henceforth referred to as “3nt-seq” or “5nt-seq”, respectively; these are simply variables indicating occurrences of A, G, C or T at each position), the mutation count of the tri/pentanucleotide in that tumor sample, and its occurrence within the human reference genome GRCh37/hg19 (the latter was introduced as an offset value into the regression, thus adjusting for the differential occurrence of oligonucleotides in the genome sequence). For DNA structural features, the sets of all structural parameters extracted for pentanucleotide and heptanucleotides (henceforth, “5nt-str” and “7nt-str”), each divided into L, M, and H bins, was used in place of the 3nt-seq or 5nt-seq in the DNA sequence analysis. The McFadden pseudo-R^2 (henceforth, pR^2) statistic was used to evaluate model performance, for each set of features and for each of the six tumors. All Poisson regression analyses and visualization were performed with R 3.6.[38]

Estimating systematic variation in mutational patterns by principal component (PC) analysis and non-negative matrix factorization (NMF)

PC analysis was performed jointly for blocks of features describing the DNA sequence, and features describing DNA structure. On the DNA sequence side, 96 mutation contexts were considered within each tumor sample. In order to keep the number of structural features the same, thus making the estimations of relative contributions of sequence and shape parts toward each principal component balanced, we prepared 96 mutation contexts on the DNA shape side. This was achieved by focusing only on the L/M/H binned (see above) features of the six DNA structure parameters with the highest potential for interpretation: *mgw*0, *prop*0, *ro-1*, *ro*+1, *tw*-1, and *tw*+1. Six parameters could sample a conformational space assigned to one of the three bins: L, M, and H, generating 18 features, which were examined separately for six mutation types (C>A, C>G, C>T, T>A, T>C, T>G; considered DNA strand symmetrically) and thereby a total of one hundred eight contexts were obtained. After removing energetically forbidden (not sampled), conformational parameters: *prop*0*(L)* and *ro*-1*(H)* on the C sites, and *prop*0*(H)* and *tw*+1*(L)* on the T sites, the number 108 was reduced by 12 and resulted in 96 mutation contexts on the DNA structural side. Next, mutation counts in the structural block of each tumor sample were adjusted to match the sequence contribution to mutation burden in the corresponding sample, i.e., sampled to sum to the same values for the DNA sequence feature block and the DNA structure feature block. Additionally, the DNA structural features block was adjusted to have equal counts to the DNA sequence feature block, using a sampling function with the *UPmultinomial* function in R package *sampling*.[38] In this way, the noise due to low mutation counts will be equal in the two feature blocks and will not bias the PC analysis toward one block of features.

Our application of NMF to extract mutational signatures in parallel from trinucleotide mutational spectra and from DNA structural features (same set as for the PC analysis) was performed as follows. We extracted cancer cell line mutational signatures from 96 component trinucleotide mutation spectra and 96 DNA structural features of WGS samples. To extract mutational signatures we used custom R[21] implementation of the non-negative matrix factorization (NMF) based methodology, broadly as described by Alexandrov et al.[1] From the matrix containing mutation spectra and DNA structural

features of samples, we generated 300 bootstrap samples. One bootstrap sample is obtained with *sampling* function of the *UPmultinomial* R package[38] applied to each sample's spectrum. Next, we used the NMF algorithm to each of the bootstrap samples (*nmf* function of the *nmfgpu4R* R package) to get different NMF runs; we used the *Multiplicative update rules* algorithm[43] with 10000 as the maximal number of iterations). For each bootstrap sample, we varied the number of signatures. We used the 'hierarchical extraction' procedure proposed by Alexandrov et al.[1] where NMF is iteratively repeated while removing the well-reconstructed samples (cosine similarity above 0.97) from a previous iteration to discover new signatures. We allowed a maximum of 3 iterations.

From all the candidate mutational signatures obtained, we first searched for the signatures that closely resembled the ones that were previously found in human cancers[1] (referred to as PCAWG signatures). We compared the individual signatures obtained by all the different runs of NMF (given the different bootstrap samples and the different number of signatures) to the PCAWG signatures. For this comparison we calculated the cosine similarity on the 96 trinucleotide spectra (the 96 DNA structural features were not used). For each PCAWG signature, we searched for the closest matching NMF run. As a final set of mutational signatures, for each PCAWG signature we kept the closest matching NMF run if its cosine similarity to the best matching PCAWG signature exceeded 0.85. We use the NMF scores as the signature exposures across different tumor samples.

This procedure yielded 54 mutational signatures. The obtained signatures are named according to the PCAWG signatures they resemble, e.g., the signature name SBS15/6L denotes this signature was the closest match to PCAWG SBS15 (i.e., SBS15 is the primary signature); 6L denotes that the signature also resembled PCAWG signatures SBS6 (cosine similarity > 0.85). The "SBS" stands for "single base substitution"; here we do not consider indels or structural variation signatures. The suffix "L" (for "like") denotes 0.85 ≤ cosine similarity < 0.95 (a somewhat less-close match), while the

absence of the suffix “L” means cosine similarity ≥ 0.95. Names of signatures other than the primary signature (if present) are ordered by decreasing cosine similarity.

We next searched for signatures specific to our dataset, i.e., signatures that commonly appear in our data but do not resemble any of the known tumor signatures. To this end, we employed k-means clustering (*clara* function in *clusters* R package, with Euclidean distance, standardization, “pamLike” options and the number of samples to be drawn from the dataset set to 10%). Each batch of the NMF solutions (from the signature extraction method selected as final by the evaluation) obtained as described before (one batch consists of 300 x *n* solutions, where *n* is the number of signatures; varies from 2 to 40) was clustered into *k* clusters with k-means clustering varying k from 2 to 40. We chose the clustering result (i.e., a set of signatures) where the agreement with PCAWG signatures was maximized in terms of the number of clusters medoids that resemble PCAWG signatures (at cosine similarity >0.85). From such a set of signatures we selected the ones dissimilar from any of PCAWG signatures (cosine similarity <0.8), yielding in total 6 structural signatures denoted as SBS-SS (SBS structural signature).

Results

Based on the known individual examples of DNA structural features associated with mutation occurrence via specific mechanisms,[25–28] we hypothesized that a broad set of diverse DNA structural features would be able to predict mutation rates due to many different mutagenic exposures. To test this hypothesis, we predicted mutational frequency of DNA segments using count models (Poisson regression). In brief, in this approach a certain DNA oligonucleotide can be defined either by the DNA sequence features (occurrence of A, G, C or T in each position of the flanks of a locus), or by the DNA structural features (listed in Methods), while adjusting for the total number of occurrences of that oligonucleotide in the human genome sequence. We selected six hypermutated tumor samples as representatives of important mutagenic processes: (i) microsatellite instability (MSI) caused by defective DNA mismatch repair (MMR) in a

representative colorectal tumor sample; (ii) activity of the proofreading-deficient DNA polymerase epsilon (POLE) in another colorectal cancer sample; (iii) a bladder tumor sample bearing the mutational signature of the APOBEC cytosine deaminase;[23] (iv) a lung adenocarcinoma sample highly enriched with the tobacco smoking mutational signature; (v) ultraviolet (UV) light-induced mutagenesis in a melanoma sample; and (vi) the hypermutation induced by therapy by the DNA methylating drug temozolomide (TMZ) in a glioblastoma sample. Such hypermutated tumors derive most of their mutations from a single mechanism. This allowed to examine the mutagenic processes individually and to identify the sequence features and/or structural features of highly mutable DNA oligomers.

Sequence and structural features of oligonucleotides that hypermutate upon DNA repair failures

The Poisson regression coefficients corresponding to DNA sequence features – derived from trinucleotide (Figure 2A, “3nt-seq”) and pentanucleotide (Figure 2B, “5nt-seq”) neighborhoods – quantify the impact of flanking DNA sites on mutational risk of the central site. For example, in the MSI tumor (Figure 2A), the central cytosine, C, (or, equivalently, the guanine, G, it pairs with) is more mutable than the thymine, T (equivalently, adenine, A). Furthermore, a guanine in the immediate 3’ flanking position (“+1” in Figure 2A, MSI tumor) is further associated with a higher mutation rate of the central nucleotide in this tumor, consistent with very high mutation rates of the (commonly methylated) CpG dinucleotide in MMR-deficient cancers,[44] and consistent with the mutational signature SBS6 previously detected for many colorectal cancers with MSI.[1] The extended pentanucleotide neighborhood appears to have more subtle associations with the MSI mutagenesis, at least in this particular MSI tumor; nonetheless some enrichment with cytosine at -2 and +2 positions were observed (Figure 2B)



Figure 2. DNA sequence as predictor of mutational burden in tumor samples by mutagens: MSI, POLE, APOBEC, smoking, UV, TMZ. N can be any of the four DNA bases: A, C, G, or T (color coded respectively: dark green, light green, light blue, or dark blue). Poisson regression coefficients for (A) 3nt-seq, and (B) 5nt-seq. Error bars superimposed on each symbol show 95% C.I.

Next, we turned to examine the DNA structural features that associate with mutation occurrence in the MSI tumor sample (top row, Figure 3A, “5nt-str”). We examined Poisson regression coefficients for the high “(H)”, medium “(M)” and low “(L)” bins of each structural feature, as derived from the pentanucleotide neighborhoods (see Methods). Among other features, we observed a slight positive association with the *mgw*0*(H)* bin (pentanucleotides with high minor groove width at the central position), as well as with the *tw*+1*(L)* bin (a low value of twist parameter for the +1 position; see Figure 1 for schematic). A further analysis using structural features derived from an extended, heptanucleotide neighborhood (“7nt-str”; top row, Figure 3B) confirm the above and further suggest a narrowing of the minor groove at the position +1. To quantify the overall utility of DNA structural features for predicting mutation rates, we

examined the overall fit of the model *via* the McFadden pseudo-R^2 statistic (pR^2; see Methods). The DNA structural features exhibited a higher predictive ability (pR^2=0.60 for the *7nt-str*) compared to the composition DNA sequence features (highest pR^2=0.56 for the *5nt-seq*). We note that our shape features were computed from the DNA sequences by employing data resulting from previous simulations of DNA structures of various oligonucleotides (see Methods). This increase in model fit by using the DNA structural features indicates that they capture those statistical interactions between sites in a DNA motif that are relevant for predicting mutability of the oligomer. In other words, this representation of DNA shape preserves the important information for describing mutation rates while ignoring the less important information, suggesting that DNA structural descriptors may be a useful representation for mutational signature analysis. In addition, structural features highlighted by the regression (see above) may have potential for interpretation of mutagenic mechanisms in MMR-deficient, MSI tumor samples.



Figure 3. Poisson regression coefficients describing mutation rates resulting from six mutagenic processes (MSI, POLE, APOBEC, SMOKING, UV and TMZ) evaluated from (A) 5nt-str, and (B)

7nt-str representations. Parameters were normalized and divided into 3 equally spaced bins: high, medium, and low. Error bars are 95% C.I.

Next, we turned to examine mutations resulting from another sort of DNA repair failure common in tumors – deficient proofreading activity of the replicative DNA polymerase epsilon due to a mutation in the POLE gene.[45] In the POLE-signature enriched colorectal tumor sample (POLE row, Figure 2), the landscapes of regression coefficients from DNA sequence features contain many noticeable signals located further from the central nucleotide, consistent with previous work that suggested that up to nonanucleotide (9-mer) sized DNA motifs are informative for POLE mutagenesis.[15] We detected enrichments of thymine and to some degree adenine at -2, -1, +1 and at +2 positions next to the mutated central cytosine (Figure 2). The observed pattern resembles the mutational signatures SBS10a and SBS10b detected in colon and uterus cancers,[1] further supporting the use of our methodology based on count models (here, Poisson regression) to model mutation risk. More interestingly for the matter at hand, the DNA structural analyses of the mutated loci in the POLE tumor (Figure 3) show strong signal in the twist at -1 and +1 positions, where DNA is over-twisted and under-twisted, respectively. This suggests there is a local deformation at the POLE hypermutable sites, tapering off towards a more regular shape further away from the center. As with the MSI tumor, the overall fit of the predictive model in the POLE tumor, the structural DNA features compared favorably (pR^2=0.81 for *7nt-str*, Table 1) to the sequence DNA features (pR^2=0.81 for *5nt-seq*), further supporting that the structural features we examined are appropriate to describe the propensity of DNA sites to mutate in DNA repair-deficient tumors. The overall predictive accuracy was higher for the POLE tumor than for MSI tumor (Table 1), suggesting that mutational risk can be predicted from DNA shape to a variable degree across different mutational processes.

Table 1. Performance of four models: 3nt-seq, 5nt-seq, 5nt-str, and 7nt-str. Representative of distinct mutational processes, each row is a tumor sample with one strong mutational exposure.

Predominant signature	Cancer type	Hypermutation type	McFadden R^2			
			3nt-seq	5nt-seq	5nt-str	7nt-str
SBS6	COAD	MSI	0.57	0.56	0.55	0.60
SBS10	COAD	POLE	0.86	0.81	0.76	0.81
NA	BLCA	APOBEC	0.94	0.92	0.77	0.85
SBS4	LUAD	SMOKING	0.98	0.83	0.85	0.50

SBS7	SKCM	UV	0.89	0.82	0.66	0.74
NA	GBM	TMZ	0.78	0.58	0.52	0.28

Structural features associated with mutagenesis due to an endogenous DNA damaging activity of the APOBEC3A enzyme

In addition to examples of DNA repair deficiencies that result in hypermutation (MSI, POLE), we next turned to examining DNA structural features of sites mutated by DNA damaging agents. This included examples of both endogenous (APOBEC cytosine deaminases) or exogenous agents: radiation (UV) and chemicals (tobacco smoke, and the DNA methylating drug TMZ). Regression on trinucleotide contexts in the APOBEC-enriched bladder cancer sample shows a very strong association of thymine at -1 position with mutation risk (Figure 2A, APOBEC row), as expected from known mutational signatures SBS2 and SBS13.[2] The pentanucleotide regression (Figure 2B) finds enrichment of pyrimidines at position -2, supporting the role of the APOBEC3A enzyme[46] rather than the APOBEC3B paralog in mutagenizing this particular tumor. This is consistent with high propensity towards APOBEC3A mutagenesis in bladder cancer.[47] With respect to the DNA shape analysis, we note that APOBEC binding and deamination occurs on single stranded DNA, where DNA shape parameters have altered interpretation or are not well defined. However, the steps following the APOBEC-mediated DNA damage (i.e., cytosine to uracil conversion), involving repair by the base excision repair pathway (e.g., the UNG protein), can involve double-stranded DNA, making the structural features we examined also pertinent to APOBEC mutagenesis. The local tendency towards over-twisting at -1 and then under-twisting at +1 position is evident from the DNA structure coefficients (Figure 3A). Structural features in a broader DNA context (Figure 3B, *7nt-str*) additionally show that position -2 exhibits under-twisting at APOBEC3A mutated sites. Considered together with over- and under-twisting at positions -1 and +1, respectively, this suggests that DNA motifs experiencing APOBEC mutagenesis may be more prone to have flipped out bases. There are no notable changes in the roll parameter, suggesting it is not DNA bending that affects APOBEC mutation frequency but rather the tendency toward exposing a single (here, central) nucleobase. Further supporting that a broader DNA oligomer context is predictive for APOBEC mutagenesis, the model fit of the *7nt-str* descriptors is

higher than for *5nt-str* descriptors (Table 1). We note that the simple trinucleotide representation of DNA sequence is highly predictive (Table 1), probably reflecting the strict requirement for 3' T in APOBEC mutagenesis.

DNA structural features confer risk of mutation resulting from exogenous DNA damaging agents

Turning towards exogenous mutagenic agents, we examined a tobacco smoking-enriched lung adenocarcinoma sample. Such tumors are predominantly associated with the signature SBS4, consisting of C>A mutations in various trinucleotide contexts.[1,2] In accordance with SBS4, the trinucleotide and pentanucleotide DNA sequence coefficients do not indicate preferences towards certain nucleotides in the flanking sequence of the central C (Figure 2, "smoking" row; of note there is a slight preference towards upstream C). This is also reflected through the DNA shape, where the associations with mutational burden are likewise subtle when considered individually (Figure 3, "smoking" row). There are, for instance, positive associations of higher values of propeller and roll parameters at positions 0 and +1, respectively, with mutation risk due to smoking chemicals. When considered jointly however, the DNA structural features do convey much information with predictive potential, which matches or exceeds the other considered mutational signatures (pR^2=0.85 for the *5nt-str* approach, Table 1).

In addition to the chemical mutagenesis in lung, we also examined mutagenesis due to radiation (here, UV light) in a melanoma skin cancer genome using the Poisson regression analysis (Figure 2, "UV" row). It is known that pyrimidine base pair steps define the hotspots for electron excitation by UV light, leading to the formation of cyclobutane dimers.[48–50] The condition of having TC or CC steps for the excitation process is reflected in the known mutational signatures SBS7a and SBS7b, as well as in our regression analysis using trinucleotides (*3nt-seq*, Figure 2A). Moreover, we observe the association of mutation risk with flanking T at positions -2 and +2 (*5nt-seq*, Figure 2B). This is consistent with previously reported pentanucleotide contexts for the

C>T UV-associated mutations.[51] The DNA shape analysis also reflects related trends:. for example, a strong signal is observed for "*tw*-1*(H)*" (high twist at the -1 position), which is known to reach its highest values at TC base pair steps.[32,52] Overall, the UV radiation induced mutation propensity of a site was highly predicable from the heptanucleotide-derived DNA shape features (*7nt-str*, pR^2=0.74, Table 1), similarly as for the DNA repair-related POLE (0.81) and APOBEC (0.85) mutagenesis. Thus, DNA shape features are useful to predict occurrence of mutations resulting from various causes, although we recognize this will not necessarily be the case for every mutagen to the same extent.

We examined a further chemical mutagenic agent by studying a temozolomide (TMZ)-treated glioblastoma tumor genome (Figures 2 and 3, TMZ row). TMZ is a DNA alkylating agent and its signature SBS11 has been detected in copious amounts in TMZ-pretreated tumors.[1] We note subtle associations with individual descriptors in all four groups of DNA shape features (*mgw*, *prop*, *roll* and *twist*; Figure 3). Compared to the other mutagenic agents considered, the DNA shape features considered jointly appeared less predictive for TMZ mutations (Table 1). This suggests that either DNA shape is less important for activity of this chemical mutagen, or that our set of shape features does not incorporate those features that are relevant for TMZ mutagenesis. However, an overall pR^2 of 0.52 (at *5nt-str*) implies there is still some signal relevant for predicting TMZ mutations embedded in the DNA shape descriptors.

A comparison of performance of the Poisson regression models in predicting mutability of oligonucleotides suggests that the *7nt-str* model tends to be more predictive (higher pR^2) than *5nt-str*, at least for four of the six considered types of hypermutation. This indicates that the shape of DNA in broader, heptanucleotide neighborhoods is relevant for the intensity of many mutational processes. The pentanucleotide-based DNA structure model has overall similar accuracy to the sequence-composition based (*3nt-seq* and *5nt-seq*) predictors, although their relative ranking is variable across different mutagens.

Overall, the set of DNA shape features we examined is broadly reflective of oligonucleotide properties relevant for mutagenesis. Nonetheless we recognize that this set may be further refined, thus possibly improving its accuracy in predicting DNA mutational hotspots for a broader range of mutagens.

DNA shape features capture the variability in mutational exposures across individuals

Above, we have shown that DNA structure-based descriptors were associated with mutation risk resulting from exposure to diverse mutagens. Some of the shape features appeared to commonly predict higher mutation rates resulting from different mutagens (e.g., under-twisting at +1 position, Figure 3). However, many other features appeared associated with some mutagens but not with others (e.g., high roll at +1, low minor groove width at +1, high propeller at -1, etc.; see Figure 3). Thus, we hypothesized that DNA shape descriptions of mutated loci in a genome sequence could be used to quantitate mutagenic exposures that cell has undergone previously. In other words, use of DNA shape features would enable a novel conceptualization of mutational signatures.[1,2] Mutational signatures are usually defined via trinucleotide neighborhoods of mutated loci, but broader neighborhoods were also considered previously (which however means that statistical interactions between nucleotides may need to be ignored).[53] To derive mutational signatures, various forms of factor analysis can be applied to the mutation frequency data; commonly, non-negative matrix factorization (NMF) was used[2] although not exclusively.[22] Here, we evaluated the potential of DNA shape descriptors to generate informative mutational signatures. To this end we employed a principal components (PC) analysis to generate mutational signature PCs and measure the amount of systematic variability in the data, here implying the differential exposures to mutagenic effects across tumor samples. In the PC analysis, we used either the mutability of various DNA trinucleotides (sequence descriptors, *3nt-seq*) or mutability of various DNA shapes (*5nt-str* features; for the PC analyses, DNA shape features were adjusted to match the number of the DNA sequence features, see Methods for details). Both sets of features were included simultaneously in a PC analysis of somatic mutations from 1637 whole-genome sequences of tumors of various

cancer types. Results showed that DNA structure features could explain a higher amount of the systematic variance than the DNA sequence features, when considering four out of the five dominant PCs: PC1, PC2, PC3, and PC5 (the PC analysis scree plot, broken down into the DNA sequence-feature part and the DNA shape-feature part, is shown in Figure 4A). Overall, the top five PCs explained 85.6 % variance in the mutation rates of DNA oligonucleotides across tumors, with the sequence features covering 40.6%, and structural features 45.0% variance (Figure 4B). The excess of variance-explained by the structural features amongst the top PCs (Figure 4B) suggests they are more descriptive markers of the variability in mutagenic processes between human tumors, when compared to a standard DNA sequence representation using trinucleotides. Thus, DNA structural features are well-suited for inferring mutational signatures.



Block	PC1	PC2	PC3	PC4	PC5	PC6	PC7	PC8	PC9	PC10
Sequence	21.83	8.12	4.72	3.96	1.94	1.83	1.83	1.17	0.70	0.79
Shape	23.70	8.54	6.31	2.60	3.86	1.35	1.00	0.86	0.41	0.27

Figure 4. PC analysis of DNA sequence and structural features in 1,637 cancer genomes in 30 cancer types. (A) Top 10 PCs separated into sequence and structural contribution (baseline is the half of a 'broken stick' estimate). (B) Numerical representation of each PC's contribution to the overall variance in the sequence or structure block. (C) PC1 vs. PC2 scores, (D) PC2 vs. PC3 scores, (E) PC3 vs. PC4 scores, (F) PC4 vs.PC5 scores, (G-H) Examples of PC1 and PC2

scores of cancer samples separated into smaller groups of tissues, (K-L) Examples of loadings between PC1 – PC2 and PC2 – PC3 corresponding to the (C) and (D) PC scores.

Over 45% of the variation that is explained by the dominant, first PC contains contributions from both the DNA shape features (23.7% variance) and from the DNA sequence features (21.8% variance). All mutation features had positive loadings on the PC1 (Supplementary Table S1), indicating that the PC1 reflects the overall mutation burden across tumors, rather than the differential mutational signatures. We noted a consistently high PC1 loading on the various types of mutations at loci with low DNA roll at -1 position ("ro1L"; Supplementary Table S1) suggesting this structural feature may be associated with higher DNA mutability generally i.e., in a manner not related to a particular mutagen. Furthermore, high-*mgw* and low-*twist* loci mutation frequencies had high PC1 loadings across multiple mutation types (Supplementary Table S1), suggesting additional structural features that characterize mutation-prone DNA loci, either due to being prone to various types of DNA damage, and/or less accurately copied or less efficiently repaired.

In PC2 and the following PCs (Figure 4C-F), both positive and negative loadings of different DNA sequence features and structural features were observed. This means that these PCs can distinguish relative contributions of mutational processes across individual tumors i.e., the PCs constitute mutational signatures in a broad sense. Expectedly, these PCs distinguish between abundance of six different mutation types across individuals, for instance PC2 contrasts genomes rich in C>G and/or C>A changes, from the genomes rich in A>C or A>G changes (see Supplementary Table S1). In addition to contrasting mutation types, the PC mutational signatures further distinguish between DNA structure and/or sequence contexts within each mutation type (see Supplementary Table S1). For instance, the PC2 – the dominant direction of differential mutability in our analysis – has high loadings (absolute value) for DNA under-twisting at the +1 position ("tw+1L" feature; Supplementary Table 1), mostly across the C>G and A>C mutation type. Thus, diverse types of structural features appear to describe the differential mutation rates of DNA oligomers across individuals.

We note that DNA sequence features may also have high contributions to some of the top PCs (particularly PC4, PC7; Figure 4A), suggesting that both DNA sequence features and the and DNA structural features should be considered jointly when inferring mutational signatures.

To further examine how the dominant mutational processes (here: first two PCs) vary across different types of cancer, we divided the full dataset (from Figure 4C) into smaller groups containing diverse cancer types (Figure 4G, H; The PC loadings of each original variable are plotted in Figure 4I, J). Again, the PC1 components have only positive loadings, describing overall mutation burden, while the PC2 and following describe differential mutation rates across DNA structural features (Figure 4I, J). In the various groupings of cancer types tested, the PC2 separates between cancer types: colorectal cancer *versus* others or uterus cancer *versus* others (Figure 4G, H), suggesting the ability of the DNA shape descriptors to capture tissue-specific mutational processes.

Deriving mutational signatures by combining DNA trinucleotide sequence and DNA pentanucleotide structural features

The above analyses based on PC analysis suggest that DNA structure features of mutated loci can disentangle mutational processes affecting genomes of individuals. Mutational signature studies commonly employed NMF, a technique assuming additivity of the biological processes generating mutations;[54] this is seen as a desirable property for generating robust catalogs of mutagenic mechanisms. We adapted the NMF-based methodologies for mutation signature extraction (see Methods) to jointly incorporate a selected set of 96 oligonucleotide structural features, alongside the more standard set of 96 trinucleotide-based mutation types (16 trinucleotides x 6 mutation types). Our method can extract signatures that resemble the known “SBS” (single-base substitution) signatures from the Catalogue of Somatic Mutations in Cancer (Cosmic)[55] in their trinucleotide spectrum, while additionally having a contribution from a set of DNA structural features, which may aid signature inference and interpretation. From the somatic mutations in 1637 considered cancer WGS, we recovered 48 such known signatures (matching one or more Cosmic SBS at a cosine similarity >0.85 in the

trinucleotide spectrum). We further extracted 6 additional SBS-SS (structural signatures) which were novel i.e., their trinucleotide spectrum did not match a known Cosmic SBS, meaning that they were not previously identified using trinucleotide analysis. The spectra of the composite structure-trinucleotide signatures are shown in Figure 5, and their exposures across cancer types in Figure 6 (data is in Supplementary Table S1).


SBS5L
C>A
C>G
C>T
A>T
A>G
A>C
mgw
pro
ro
tw
SBS1
SBS2
SBS3L
SBS4
SBS6/1L
SBS7a
SBS7b
SBS7c
SBS8L/4L
SBS10a/56L
SBS10b
SBS11L/23L/7bL
SBS12L
SBS13
SBS14L
SBS15/6L
SBS16
SBS17aL
SBS18/36L
SBS19
SBS20L
SBS23
SBS24L
SBS26L/12L
SBS27L
SBS28L
SBS29L
SBS30L/7bL
SBS31L
SBS32L
SBS34
SBS36/18L/56L
SBS37L
SBS38/45L
SBS39L
SBS40L/3L
SBS42L
SBS44L
SBS45/38L
SBS46L
SBS49
SBS52
SBS53/38L
SBS56/10aL/36L
SBS57L
SBS58L
SBS59L
SBS-SS1
SBS-SS2
SBS-SS3
SBS-SS4
SBS-SS5
SBS-SS6

Figure 5. Mutational spectra based on DNA structural features. The composite mutational signatures consist of 96 DNA structural features: mgw and propeller at the central nucleotide (dark brown and light brown bars, respectively), roll and twist at -1 and +1 sites (dark yellow and light yellow bars, respectively), and the standard 96-component trinucleotide spectrum (blue, black, red, grey, green, pink bar colors).

Firstly, we examined the DNA structure part of the spectra of some of the known SBS signatures, suggesting possible insights into mechanisms of mutagenesis. Several examples are highlighted below:

SBS4 (tobacco smoking associated, likely resulting from bulky adducts e.g., by benzo[a]pyrene metabolites and related chemicals, typically onto guanine bases). This mutational process impacts regularly organized DNA structure, i.e., upon mutation, no specific deformations at C:G nucleotide pairs seem necessary for the mutagens to bind DNA. The less common mutations that occur at the A:T nucleotide pairs suggest slight preferences toward narrower minor groove and lower twisting at -1 position versus lower twist at +1 position, and higher propeller at the central base pair for A mutations to T or G respectively, suggesting an increased exposure at these sites.

SBS6/1L (one of the signatures associated with DNA MMR failures). With the expanded minor groove, there is a potential for kinks occurring on DNA due to the positive or increased roll values at the adjacent bases, leading to a simultaneous compression of the major groove. It is conceivable that MMR proteins might act preferentially upon DNA with certain subtle conformational variations, increasing efficiency of repair at these loci.

SBS 7a, and similarly but to a lesser extent **SBS 7b** (UV exposure-associated mutational signatures, likely resulting from cyclobutane pyrimidine dimer formation). Series of positive roll values at the bases to the C>T mutation suggest a DNA structural motif with propensity toward the three-dimensional writhe, but a smooth curvature, which may either increase exposure to the damaging agent, or disfavor error-free lesion bypass or repair.

SBS 10a (associated with mutations in the proofreading domain of the replicative DNA polymerase epsilon). Signature 10 mutated loci have a characteristic combination of a

high twist at -1 position followed by a low twist at +1 position, suggesting untwisting of DNA at the mutated base pair step immediately before overtwisting. This, together with a slight preference toward the *mgwH* and moderate roll values at the adjacent base pair steps, suggest a stronger kink or bending may occur. Such large conformational bias can conceivably impede replicative DNA polymerases, increasing mutation rates during their proofreading activity.

SBS2 and **SBS13** (resulting from the activity of the APOBEC3A and/or APOBEC3B cytosine deaminases). The set of DNA shape descriptors employed results in a nondescript signal for these signatures, when compared with other mutators considered. Given that APOBECs are active exclusively on ssDNA, this relative lack of utility of double-stranded DNA shape information is perhaps expected to some extent and suggests that additional descriptors may be helpful to better model the APOBEC proteins recognition of DNA.

Next, we examined the spectra of 6 novel mutational structural signatures (SBS-SS). These did not closely match an existing Cosmic SBS trinucleotide profile, suggesting that analysis of the DNA structural descriptors helps identify these novel signatures. We comment on these examples below:

SBS-SS1 signature somewhat resembles signature SBS12 in the trinucleotide spectrum, in that they are enriched mainly in the A>G block, however SBS-SS1 does additionally encompass some C>A, C>T and A>T changes (Figure 5). The SS1 shape analysis suggests higher propensity for DNA bending caused by stretching of the minor grove (*mgwH*) supported by potential kinks due to high at roll +1 (*ro*+1H). Preference of low twist values at -1 and +1 additionally suggest unwinding of DNA, increasing the exposure of DNA bases. These structural changes are indication of deviation from the canonical B-DNA structure toward A-DNA. Such deviations could not be detected with the DNA trinucleotide signature analysis only. In terms of exposures, this SBS-SS1 is widespread across tissues with a somewhat similar distribution as SBS-SS3 (Figure 6). This suggests that both SBS-SS1 and SBS-SS3 might have resulted from variations on a common mechanism of DNA replication or repair, present across various cell types.

SBS-SS2 is characterized by mutations occurring mainly in the A>G block (Figure 5), where the trinucleotide spectrum (WAW, where W = A or T) resembles that of the error-prone DNA polymerase eta (POLH protein). This was seen in clustered mutational signatures in many cancer types, predominantly skin, liver, bladder, the digestive system and lung,[47] as well as in the lymphoid cells because of the (non-pathogenic) process of somatic hypermutation. Similarly, the SBS-SS2 has the highest exposures in skin, liver, bladder and lymphocytes (Figure 6), supporting the connection, and suggesting a structural basis for the mutability due to use of an error-prone DNA polymerase.

SBS-SS3 has a recognizable structural feature across A>C and A>T blocks where the minor groove is compressed (*mgwL,* Figure 5). SS3 shows less DNA distortion in the A>G block, with a weaker signal for disrupted hydrogen bonding that can be recognized through the high values of propeller base pair parameter (*proH*). These observations suggest that within the SBS-SS3 signature, conformational DNA changes might occur on the larger scale (because of the compression of the minor groove repeated in two blocks, which might have an impact on the neighboring steps), without large displacements in the local base pair arrangements. With respect to the exposures (Figure 6), SBS-SS3 is commonly observed across many different cancer types, with highest values in lung squamous cell carcinoma, in B-cell lymphoma, in ovarian, stomach and bladder cancers. The wide occurrence suggests this signature is due to a ubiquitous, endogenous process in replicating or repairing DNA, rather than an exposure to a particular carcinogen.

SBS-SS4 signature's distinguishing feature is the proximity of low twist values in the adjacent base pairs associated with low roll values. Typically, the similar trends in twist and roll – either both low or both high – are rarely observed at the same base pair step, suggesting prevalence of purine-purine (RR) motifs. The presence of RR steps is supported by the signals observed in the SBS-SS4 trinucleotide spectra where a higher mutational frequency of GAA, GAC, GAG, GAT and TAA sequences is detected.

SBS-SS5 displays a variety of structural geometries depending on which type of A>N mutation is considered; the A>C changes appear dominant (Figure 5). Within the A>C block there is a preference for either compressed or extended minor groove width, with a lower preference toward regular width. This changes when mutations occur in the A>T or A>G block: compressed or extended minor groove widths (*mgwL*, *mgwH*) are preferred, respectively. These observations suggest influence of both DNA sequence and the DNA conformation on the recognition of DNA by the mutagenic agents. The high exposure of this signature in the esophagus, stomach, colon and lymphoma (Figure 6) suggests a relationship with the known signature SBS17b (which is also A>C rich and occurs in these tissues) however the trinucleotide spectra are sufficiently different that it was identified as a separate SBS.

SBS-SS6 contains mutations of the A>C and C>T types (Figure 5) and is rarely occurring (Figure 6). The strong compression of the central minor groove might suggest a preference for helix-turn-helix binding protein domains, or for proteins further compressing the minor groove, yet the preference for the simultaneous expansion of minor groove is intriguing and could be further explained by different content of purines and pyrimidines in the adjoining bases.



Figure 6. The exposures of structural mutational signatures from Figure 5 across different cancer types. The mean exposure is shown.

Discussion

Our work highlights the ability of DNA shape features to predict mutational risk of individual genomic loci in cancers exposed to various mutagenic processes, ranging from DNA repair failures to mutagenic chemicals or radiation. Our predictive models further showcase the ability to identify DNA structural determinants associated with each mutagenic process. Many of the known trinucleotide mutational signatures appear to have informative structural components of the spectra. Such associations of mutation risk with DNA structural features may potentially further our understanding of the underlying mechanisms of DNA damage and repair. Furthermore, we demonstrate that the DNA shape features of the mutated loci can capture a higher amount of systematic variability in mutational processes across cancer samples than a naive representation of DNA sequence via oligonucleotides, as commonly employed. Consistently, using structural features, novel mutational signatures can be extracted that may not be within reach of oligonucleotide-based approaches. We note that these two groups of features (DNA shape and DNA sequence) are to some level redundant – expectedly so, given that the shape features were derived using a method based on oligonucleotide dictionaries. Importantly, however, the DNA shape features represent a tradeoff between complexity and informativeness; They capture certain interactions across neighboring nucleotides within a pentanucleotide or longer neighborhood, while keeping the overall representation relatively simple (not all statistical interactions between nucleotides are modeled). This makes DNA structure useful for analysis of -- relatively sparse -- mutation count data. If the full set of statistical interactions was included for DNA sequence representations, the number of features would rise exponentially, making it unfeasible to apply to contexts longer than pentanucleotides (we note that for the exome sequencing data, which is most abundant, even the pentanucleotides are out of reach because of small number of mutations per tumor). Use of structural DNA features however makes such analyses of broader contexts feasible. This is clearly of interest, given that heptanucleotide and even nonanucleotide contexts appear relevant for some mutagenic processes, such as UV mutagenesis,[51] POLE mutagenesis in cancers,[15] and also certain mutational processes in the human germline.[56,57] Overall, we

suggest that use of structural DNA features may help overcome hurdles for analyzing the roles of longer oligonucleotide neighborhoods as determinants of DNA mutability.

There is a growing awareness that analysis of somatic mutation data may be able to guide personalized therapy for cancer patients. Current focus is on refining drug selection to match the underlying genetic profile of tumors.[58,59] This normally entails matching certain driver mutations to targeted drugs (e.g., *EGFR* or *BRAF* mutations or *HER2* amplifications are commonly exploited in the clinic, but many more are investigated).[60] However, in addition to driver changes, another genetic marker of rising importance are genomic profiles of mutational signatures. Because these reflect ongoing genomic instability, which is common in tumors, they could help better stratify patients for targeted therapies. This is exemplified in signatures of deficiency in DNA MMR nominating patients for immunotherapy.[61,62] The mutational Signature SBS3 and also a pattern of deletions with microhomology signal failures in the homologous recombination repair (HRR) pathway (commonly via loss-of-function in the *BRCA1* or *BRCA2* genes), which is a vulnerability targetable by PARP inhibitors.[19,20] This principle may extend beyond MMR and HRR deficiencies: in an analysis of mutational signatures across cancer cell lines that were screened for drug activity, many signatures were associated with drug sensitivity or resistance, suggesting some of the signatures might constitute useful genomic markers in patients.[21] In addition, mutational analysis might conceivably signal when resistance to therapy arises. For example, given that the error-prone DNA polymerase eta (POLH protein) can help overcome treatment by cisplatin,[63] identification of its mutational signatures – previously via DNA sequence features[47] but possibly also by the affinities of this error-prone DNA polymerase(s) towards certain DNA shape features (Figure 5) – could inform treatment decisions. In summary, there is great promise for clinical use genomic markers in tumors even though many mechanisms remain elusive,[60] and among such genomic markers, the utility of mutational processes in particular merits more attention.

With a joint DNA sequence and structure representation as a basis for mutation signature inference, we posit that future work will be able to disentangle the mutagenic mechanisms at increased accuracy compared to current, oligonucleotide-based representations. Moving beyond examining the relatively simple mutational landscapes

of hypermutator tumor samples – as we have done here to establish a proof-of-principle – future methods to predict mutation risk of genomic loci should also be able to accurately deconvolute mutational processes in tumors where more than one process was active. Next, our current implementation of the multi-tumor analysis to extract mutational signatures is based on a broadly standard NMF approach. Conceivably, this may further benefit from applications of sophisticated statistical approaches for mutational signature deconvolution that use e.g. topic models[64,65] and that can jointly analyze multiple 'channels' in the mutational signature signal. In conclusion, we propose a general framework for quantifying mutational signatures via use of DNA shape descriptors, which may advance mechanistic understanding of mutagenesis and identify novel processes shaping mutational landscapes across individuals.

Acknowledgements

This work has received funding from the European Union's Framework Programme for Research and Innovation Horizon 2020 (2014-2020), under the Marie Skłodowska-Curie PROBIST grant agreement No. 754510 (to A.K. and J.L., PROBIST co-fund fellowship of the Barcelona Institute of Science and Technology) and by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. 757700, to F.S). F.S. is funded by the ICREA Research Professor program. A.K., J.L. and F.S. acknowledge support of the Severo Ochoa Centres of Excellence program of the Spanish Ministry of Economy and Competitiveness to the IRB Barcelona. Work in the laboratory of F.S. was supported by the ERDF/Spanish Ministry of Science, Innovation and Universities-Spanish Research State Agency/RegioMut project (grant agreement No. BFU2017-89833-P).

References

1. Alexandrov, L. B. *et al.* The repertoire of mutational signatures in human cancer. *Nature* (2020) doi:10.1038/s41586-020-1943-3.
2. Alexandrov, L. B. *et al.* Signatures of mutational processes in human cancer. *Nature* (2013) doi:10.1038/nature12477.
3. Berger, M. F. & Mardis, E. R. The emerging clinical relevance of genomics in cancer medicine. *Nature Reviews Clinical Oncology* (2018) doi:10.1038/s41571-

018-0002-6.
4. Glockzin, G., Schlitt, H. J. & Piso, P. Therapeutic options for peritoneal metastasis arising from colorectal cancer. *World J. Gastrointest. Pharmacol. Ther.* (2016) doi:10.4292/wjgpt.v7.i3.343.
5. Nakagawa, H. & Fujita, M. Whole genome sequencing analysis for cancer genomics and precision medicine. *Cancer Science* (2018) doi:10.1111/cas.13505.
6. Seplyarskiy, V. B. et al. Population sequencing data reveal a compendium of mutational processes in the human germ line. *Science (80-.).* **373**, (2021).
7. Volkova, N. et al. Mutational signatures are jointly shaped by DNA damage and repair. *Nat. Commun.* **11**, (2020).
8. Lim, B. *et al.* Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. *Oncotarget* (2016) doi:10.18632/oncotarget.6977.
9. Muzny, D. M. *et al.* Comprehensive molecular characterization of human colon and rectal cancer. *Nature* (2012) doi:10.1038/nature11252.
10. Helleday, T., Eshtad, S. & Nik-Zainal, S. Mechanisms underlying mutational signatures in human cancers. *Nature Reviews Genetics* (2014) doi:10.1038/nrg3729.
11. Kucab, J. E. *et al.* A Compendium of Mutational Signatures of Environmental Agents. *Cell* (2019) doi:10.1016/j.cell.2019.03.001.
12. Petljak, M. *et al.* Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis. *Cell* (2019) doi:10.1016/j.cell.2019.02.012.
13. Behjati, S. *et al.* Mutational signatures of ionizing radiation in second malignancies. *Nat. Commun.* (2016) doi:10.1038/ncomms12605.
14. Poon, L. S. *et al.* Mutation signatures implicate aristolochic acid in bladder cancer development. *Genome Med.* (2015) doi:10.1186/s13073-015-0161-3.
15. Martincorena, I. *et al.* Universal Patterns of Selection in Cancer and Somatic Tissues. *Cell* (2017) doi:10.1016/j.cell.2017.09.042.
16. Dietlein, F. *et al.* Identification of cancer driver genes based on nucleotide context. *Nat. Genet.* (2020) doi:10.1038/s41588-019-0572-y.
17. Salvadores, M., Mas-Ponte, D. & Supek, F. Passenger mutations accurately classify human tumors. *PLoS Comput. Biol.* (2019) doi:10.1371/journal.pcbi.1006953.
18. Marquard, A. M. *et al.* TumorTracer: A method to identify the tissue of origin from the somatic mutations of a tumor specimen. *BMC Med. Genomics* (2015) doi:10.1186/s12920-015-0130-0.
19. Staaf, J. *et al.* Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. *Nat. Med.* (2019) doi:10.1038/s41591-019-0582-4.
20. Gulhan, D. C., Lee, J. J. K., Melloni, G. E. M., Cortés-Ciriano, I. & Park, P. J. Detecting the mutational signature of homologous recombination deficiency in clinical samples. *Nat. Genet.* (2019) doi:10.1038/s41588-019-0390-2.
21. Levatić, J., Salvadores, M., Fuster-Tormo, F. & Supek, F. Mutational signatures are markers of drug sensitivity of cancer cells. *bioRxiv* (2021) doi:https://doi.org/10.1101/2021.05.19.444811.

22. Omichessan, H., Severi, G. & Perduca, V. Computational tools to detect signatures of mutational processes in DNA from tumours: A review and empirical comparison of performance. *PLoS One* (2019) doi:10.1371/journal.pone.0221235.
23. Morgan, M. A. & Shilatifard, A. Chromatin signatures of cancer. *Genes and Development* (2015) doi:10.1101/gad.255182.114.
24. Madakashira, B. P. & Sadler, K. C. DNA methylation, nuclear organization, and cancer. *Frontiers in Genetics* (2017) doi:10.3389/fgene.2017.00076.
25. Buisson, R. *et al.* Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features. *Science (80-.).* (2019) doi:10.1126/science.aaw2872.
26. Georgakopoulos-Soares, I., Morganella, S., Jain, N., Hemberg, M. & Nik-Zainal, S. Noncanonical secondary structures arising from non-B DNA motifs are determinants of mutagenesis. *Genome Res.* (2018) doi:10.1101/gr.231688.117.
27. Duan, C. *et al.* Reduced intrinsic DNA curvature leads to increased mutation rate. *Genome Biol.* (2018) doi:10.1186/s13059-018-1525-y.
28. Mao, P. *et al.* ETS transcription factors induce a unique UV damage signature that drives recurrent mutagenesis in melanoma. *Nat. Commun.* (2018) doi:10.1038/s41467-018-05064-0.
29. Fredriksson, N. J. *et al.* Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature. *PLoS Genet.* (2017) doi:10.1371/journal.pgen.1006773.
30. Lu, X. J. & Olson, W. K. 3DNA: A versatile, integrated software system for the analysis, rebuilding and visualization of three-dimensional nucleic-acid structures. *Nat. Protoc.* (2008) doi:10.1038/nprot.2008.104.
31. Karolak, A. & van der Vaart, A. Enhanced sampling simulations of DNA step parameters. *J. Comput. Chem.* (2014) doi:10.1002/jcc.23751.
32. Olson, W. K., Gorin, A. A., Lu, X. J., Hock, L. M. & Zhurkin, V. B. DNA sequence-dependent deformability deduced from protein-DNA crystal complexes. *Proc. Natl. Acad. Sci. U. S. A.* (1998) doi:10.1073/pnas.95.19.11163.
33. Abe, N. *et al.* Deconvolving the recognition of DNA shape from sequence. *Cell* (2015) doi:10.1016/j.cell.2015.02.008.
34. Lankaš, F., Šponer, J., Langowski, J. & Cheatham, T. E. DNA Basepair Step Deformability Inferred from Molecular Dynamics Simulations. *Biophys. J.* (2003) doi:10.1016/S0006-3495(03)74710-9.
35. Karolak, A. & Van Der Vaart, A. BII stability and base step flexibility of N6-adenine methylated GATC motifs. *Biophys. Chem.* (2015) doi:10.1016/j.bpc.2015.05.001.
36. Karolak, A. & Van Der Vaart, A. Molecular Dynamics Simulations of 5-Hydroxycytosine Damaged DNA. *J. Phys. Chem. B* (2016) doi:10.1021/acs.jpcb.5b09250.
37. Northcott, P. A. *et al.* The whole-genome landscape of medulloblastoma subtypes. *Nature* (2017) doi:10.1038/nature22973.
38. R Core Computing Team. R: A Language and Environment for Statistical Computing. *R Found. Stat. Comput.* (2017).
39. Chiu, T. P. *et al.* DNAshapeR: An R/Bioconductor package for DNA shape prediction and feature encoding. *Bioinformatics* (2016) doi:10.1093/bioinformatics/btv735.

40. Zhou, T. *et al.* DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale. *Nucleic Acids Res.* (2013) doi:10.1093/nar/gkt437.
41. Lavery, R., Moakher, M., Maddocks, J. H., Petkeviciute, D. & Zakrzewska, K. Conformational analysis of nucleic acids revisited: Curves+. *Nucleic Acids Res.* (2009) doi:10.1093/nar/gkp608.
42. Zeileis, A., Kleiber, C. & Jackman, S. Regression models for count data in R. *J. Stat. Softw.* (2008) doi:10.18637/jss.v027.i08.
43. Lee, D. D. & Seung, H. S. Algorithms for non-negative matrix factorization. *Adv. Neural Inf. Process. Syst.* **13**, (2001).
44. Poulos, R. C., Olivier, J. & Wong, J. W. H. The interaction between cytosine methylation and processes of DNA replication and repair shape the mutational landscape of cancer genomes. *Nucleic Acids Res.* (2017) doi:10.1093/nar/gkx463.
45. Shinbrot, E. *et al.* Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. *Genome Res.* (2014) doi:10.1101/gr.174789.114.
46. Chan, K. *et al.* An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. *Nat. Genet.* (2015) doi:10.1038/ng.3378.
47. Supek, F. & Lehner, B. Clustered Mutation Signatures Reveal that Error-Prone DNA Repair Targets Mutations to Active Genes. *Cell* (2017) doi:10.1016/j.cell.2017.07.003.
48. Goto, N. *et al.* Detection of UV-induced cyclobutane pyrimidine dimers by near-infrared spectroscopy and aquaphotomics. *Sci. Rep.* (2015) doi:10.1038/srep11808.
49. Martinez-Fernandez, L., Banyasz, A., Esposito, L., Markovitsi, D. & Improta, R. UV-induced damage to DNA: Effect of cytosine methylation on pyrimidine dimerization. *Signal Transduct. Target. Ther.* (2017) doi:10.1038/sigtrans.2017.21.
50. Cadet, J. & Douki, T. Formation of UV-induced DNA damage contributing to skin cancer development. *Photochemical and Photobiological Sciences* (2018) doi:10.1039/c7pp00395a.
51. Pleasance, E. D. *et al.* A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature* (2010) doi:10.1038/nature08658.
52. Fujii, S., Kono, H., Takenaka, S., Go, N. & Sarai, A. Sequence-dependent DNA deformability studied using molecular dynamics simulations. *Nucleic Acids Res.* (2007) doi:10.1093/nar/gkm627.
53. Shiraishi, Y., Tremmel, G., Miyano, S. & Stephens, M. A Simple Model-Based Approach to Inferring and Visualizing Cancer Mutation Signatures. *PLoS Genet.* (2015) doi:10.1371/journal.pgen.1005657.
54. Lee, D. D. & Seung, H. S. Learning the parts of objects by non-negative matrix factorization. *Nature* (1999) doi:doi:10.1038/44565.
55. Tate, J. COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic Acids Res.* **47**, (2018).
56. Aggarwala, V. & Voight, B. F. An expanded sequence context model broadly

explains variability in polymorphism levels across the human genome. *Nat. Genet.* (2016) doi:10.1038/ng.3511.
57. Carlson, J. *et al.* Extremely rare variants reveal patterns of germline mutation rate heterogeneity in humans. *Nat. Commun.* (2018) doi:10.1038/s41467-018-05936-5.
58. Harmon, R. L. & Sugarbaker, P. H. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. *International Seminars in Surgical Oncology* (2005) doi:10.1186/1477-7800-2-3.
59. McMullen, J. R. W., Selleck, M., Wall, N. R. & Senthil, M. Peritoneal carcinomatosis: Limits of diagnosis and the case for liquid biopsy. *Oncotarget* (2017) doi:10.18632/oncotarget.16480.
60. Middleton, G. *et al.* The National Lung Matrix Trial of personalized therapy in lung cancer. *Nature* (2020) doi:10.1038/s41586-020-2481-8.
61. Schrock, A. B. *et al.* Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. *Ann. Oncol.* (2019) doi:10.1093/annonc/mdz134.
62. Sahin, I. H. *et al.* Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. *British Journal of Cancer* (2019) doi:10.1038/s41416-019-0599-y.
63. Srivastava, A. K. *et al.* Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells. *Proc. Natl. Acad. Sci. U. S. A.* (2015) doi:10.1073/pnas.1421365112.
64. Funnell, T. *et al.* Integrated structural variation and point mutation signatures in cancer genomes using correlated topic models. *PLoS Comput. Biol.* (2019) doi:10.1371/journal.pcbi.1006799.
65. Matsutani, T., Ueno, Y., Fukunaga, T. & Hamada, M. Discovering novel mutation signatures by latent Dirichlet allocation with variational Bayes inference. *Bioinformatics* (2019) doi:10.1093/bioinformatics/btz266.